Fig. 4
Plasma (a) and colonic (b) exposures of tofacitinib at its Cmax (i.e., at 30 min post-dosing) following intracecal (IC; 1 mg/kg BID) and oral (PO; 15 mg/kg BID) administration of tofacitinib to oxazolone-treated mice (n = 4 or 5). Individual data points and the mean value (±SEM) for each treatment group are shown. *** p = 0.0004 vs. Tofacitinib (15 mg/kg PO; Student’s t-test)